Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
26.80
+0.89 (3.43%)
Aug 10, 2026, 4:00 PM EDT - Market closed
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
According to 19 analysts polled by S&P Global, Ultragenyx Pharmaceutical stock has a consensus rating of "Strong Buy" and an average price target of $52.84. The average 1-year stock price forecast is 97.16% higher than the current stock price, while the lowest is $27 (+0.75%) and the highest is $96 (+258.21%).
Price Target: $52.84 (+97.16%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ultragenyx Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 13 | 12 | 12 | 12 | 12 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 20 | 19 | 19 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI | Evercore ISI | Buy Maintains $33 | Buy | Maintains | $33 | +23.13% | Aug 10, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $50 | Buy | Reiterates | $50 | +86.57% | Aug 10, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 5, 2026 |
| Wedbush | Wedbush | Hold Maintains $30 | Hold | Maintains | $30 | +11.94% | Aug 5, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $96 | Buy | Maintains | $96 | +258.21% | Aug 5, 2026 |
Financial Forecast
Revenue This Year
758.32M
from 673.00M
Increased by 12.68%
Revenue Next Year
993.78M
from 758.32M
Increased by 31.05%
EPS This Year
-3.95
from -5.83
EPS Next Year
3.19
from -3.95
EPS and Forward PE are based on non-GAAP adjusted numbers.